Quidel Corporation serves to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. As an industry leader in the introduction of rapid tests for a wide range of diseases and medical conditions, Quidel is playing a leading role in the effort to develop rapid, reliable, accessible, and innovative testing for COVID-19, including the first to market FDA EUA approval of the Sofia® SARS Antigen FIA rapid test.
Quidel products aid in the detection and diagnosis of many other critical diseases and conditions, including influenza, RSV, strep A, ocular surface disease, pregnancy, thyroid conditions, colon cancer, cardiac disease, toxicology and the only rapid diagnostic for Lyme disease. These innovative products are marketed under the Sofia®, QuickVue®, D3® Direct Detection, Thyretain®, Triage® and InflammaDry® brand names, as well as under the Solana®, AmpliVue® and Lyra® molecular diagnostic brands.
Quidel’s research and new product development engine is what has historically fueled its growth by developing a continuum of diagnostic tests from advanced immunoassay to molecular diagnostic tests to further improve the quality of healthcare not only in physicians’ offices, hospitals and reference laboratories but in emerging markets such as pharmacies, nursing homes and educational institutions. For more information about Quidel’s comprehensive product portfolio, and to explore exciting employment opportunities, visit quidel.com.